Giordano Madeddu to Humans
This is a "connection" page, showing publications Giordano Madeddu has written about Humans.
Connection Strength
0.114
-
Reply Letter - "Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis". Eur Rev Med Pharmacol Sci. 2021 03; 25(5):2161-2162.
Score: 0.007
-
Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19? Eur Rev Med Pharmacol Sci. 2021 Mar; 25(5):2435-2448.
Score: 0.007
-
Does Angiotensin II receptor blockers increase the risk of SARS-CoV-2 infection? A real-life experience. Eur Rev Med Pharmacol Sci. 2021 Jan; 25(1):523-526.
Score: 0.007
-
Editorial - HIV and cancer during COVID-19 pandemic: sailing through the perfect storm. Eur Rev Med Pharmacol Sci. 2020 12; 24(24):13103-13104.
Score: 0.007
-
Clinical features, laboratory findings and predictors of death in hospitalized patients with COVID-19 in Sardinia, Italy. Eur Rev Med Pharmacol Sci. 2020 07; 24(14):7861-7868.
Score: 0.007
-
Vaccinations in prison settings: A systematic review to assess the situation in EU/EEA countries and in other high income countries. Vaccine. 2019 08 14; 37(35):4906-4919.
Score: 0.007
-
The additional role of 18F-FDG PET/CT in prosthetic valve endocarditis. Eur Rev Med Pharmacol Sci. 2018 03; 22(6):1744-1751.
Score: 0.006
-
Body fat changes in HIV patients on highly active antiretroviral therapy (HAART): a longitudinal DEXA study. Eur Rev Med Pharmacol Sci. 2018 03; 22(6):1852-1859.
Score: 0.006
-
Tache Noire in a Patient with Acute Q Fever. Med Princ Pract. 2018; 27(1):92-94.
Score: 0.006
-
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA =50 cp/mL. Infection. 2017 Aug; 45(4):521-528.
Score: 0.006
-
The burden of HIV-associated neurocognitive disorder (HAND) in post-HAART era: a multidisciplinary review of the literature. Eur Rev Med Pharmacol Sci. 2017 05; 21(9):2290-2301.
Score: 0.006
-
SARS-CoV-2 Vaccination Among Incarcerated People: A Barrier to Overcome. Front Public Health. 2021; 9:704520.
Score: 0.002
-
Correlations Between Olfactory Psychophysical Scores and SARS-CoV-2 Viral Load in COVID-19 Patients. Laryngoscope. 2021 10; 131(10):2312-2318.
Score: 0.002
-
Systemic inflammatory markers and psychophysical olfactory scores in coronavirus disease 2019 patients: is there any correlation? J Laryngol Otol. 2021 Aug; 135(8):723-728.
Score: 0.002
-
Correlations between IL-6 serum level and olfactory dysfunction severity in COVID-19 patients: a preliminary study. Eur Arch Otorhinolaryngol. 2022 Feb; 279(2):811-816.
Score: 0.002
-
The PaO2/FiO2 ratio on admission is independently associated with prolonged hospitalization in COVID-19 patients. J Infect Dev Ctries. 2021 Mar 31; 15(3):353-359.
Score: 0.002
-
Predictors of infection, symptoms development, and mortality in people with SARS-CoV-2 living in retirement nursing homes. PLoS One. 2021; 16(3):e0248009.
Score: 0.002
-
The De Ritis ratio as prognostic biomarker of in-hospital mortality in COVID-19 patients. Eur J Clin Invest. 2021 Jan; 51(1):e13427.
Score: 0.002
-
Severity of lung involvement on chest X-rays in SARS-coronavirus-2 infected patients as a possible tool to predict clinical progression: an observational retrospective analysis of the relationship between radiological, clinical, and laboratory data. J Bras Pneumol. 2020; 46(5):e20200226.
Score: 0.002
-
Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study. Head Neck. 2020 Jul; 42(7):1560-1569.
Score: 0.002
-
Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases. Head Neck. 2020 06; 42(6):1252-1258.
Score: 0.002
-
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. J Antimicrob Chemother. 2019 09 01; 74(9):2732-2741.
Score: 0.002
-
SLAM Project - Second-Level Diagnostic Assessment: Multidisciplinary approach to HIV Patients. New Microbiol. 2019 Jul; 42(3):150-155.
Score: 0.002
-
Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials. Medicina (Kaunas). 2019 Feb 08; 55(2).
Score: 0.002
-
A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA. J Viral Hepat. 2018 12; 25(12):1406-1422.
Score: 0.002
-
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018 07 31; 18(1):357.
Score: 0.002
-
Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy. Int J Drug Policy. 2018 09; 59:50-53.
Score: 0.002
-
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018 07 01; 73(7):1955-1964.
Score: 0.002
-
Active Case Finding for Communicable Diseases in Prison Settings: Increasing Testing Coverage and Uptake Among the Prison Population in the European Union/European Economic Area. Epidemiol Rev. 2018 06 01; 40(1):105-120.
Score: 0.002
-
Underserved populations and bacterial and protozoal sexually transmitted infections: a lost health-care opportunity. Eur Rev Med Pharmacol Sci. 2017 Oct; 21(17):3935-3943.
Score: 0.001
-
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. PLoS One. 2017; 12(6):e0179254.
Score: 0.001
-
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017 04 01; 72(4):1163-1171.
Score: 0.001
-
Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and Hypertension Study. J Hypertens. 2017 02; 35(2):409-416.
Score: 0.001
-
Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. AIDS. 2017 01 28; 31(3):455-457.
Score: 0.001
-
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. AIDS. 2017 01 28; 31(3):457-459.
Score: 0.001
-
Is metabolic syndrome associated to HIV infection per se? Results from the HERMES study. Curr HIV Res. 2010 Mar; 8(2):165-71.
Score: 0.001
-
Cytological and histological diagnosis of lung cancer in Sardinia and Italy in the 1990s. Monaldi Arch Chest Dis. 2007 Dec; 67(4):179-83.
Score: 0.001